AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
BriaCell Therapeutics Corp. Warrant expiring 2031
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI AK-412096DA5B
0.89▼ 0.01 (-1.40%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.90
Day's Range
0.88 – 0.90
52-Week Range
0.61 – 1.40
Volume
11.6K
Avg Volume
15.1K
Share Statistics
Shares Outstanding
Employees
4
Exchange
XNAS
Listed
2026-01-14
Share count as of June 9, 2026

BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Market Cap?
BriaCell Therapeutics Corp. Warrant expiring 2031's Market Cap is $7.7M, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Enterprise Value?
BriaCell Therapeutics Corp. Warrant expiring 2031's Enterprise Value is -$15.1M, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's EV / EBITDA?
BriaCell Therapeutics Corp. Warrant expiring 2031's EV / EBITDA is 0.5×, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Net Income (TTM)?
BriaCell Therapeutics Corp. Warrant expiring 2031's Net Income (TTM) is -$30.7M, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's EBITDA?
BriaCell Therapeutics Corp. Warrant expiring 2031's EBITDA is -$31.9M, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Diluted EPS (TTM)?
BriaCell Therapeutics Corp. Warrant expiring 2031's Diluted EPS (TTM) is -3.53, based on as-reported figures from SEC (XBRL) filings.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Net Debt?
BriaCell Therapeutics Corp. Warrant expiring 2031's Net Debt is -$22.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BCTXLAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemApr 30, 2026Jan 31, 2026Oct 31, 2025Jul 31, 2025Apr 30, 2025Jan 31, 2025Oct 31, 2024Jul 31, 2024Apr 30, 2024Jan 31, 2024Oct 31, 2023Jul 31, 2023Apr 30, 2023Jan 31, 2023Oct 31, 2022Jul 31, 2022
Operating Expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Operating loss
Non-Operating Income (Expense)
Change in fair value of the warrant liability
Income from Equity Method Investments
Net loss for the period
Net Income Attributable to Noncontrolling Interest
Net loss and Comprehensive loss for the period attributable to BriaCell
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—